Abbreviated Name

PCA3 Ref Set App: Zhang (2019)

Lead Investigator

Zhang, Hui L. — Johns Hopkins University School of Medicine

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Zhang, Hui L. — Johns Hopkins University School of Medicine
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

see Objectives

Aims

We propose the following two aims: 1. Determine the performance of using urinary glycoproteomics and mass spectrometry for the detection of aggressive prostate cancer. We will (a) validate 4 candidate glycoproteins to detect AG PCa in diagnostic biopsy in the NCI-EDRNs Urinary PCA3 Evaluation Trial: (b) with PCA3 trial samples further develop a glycoproteomic risk score for predicting AG Pca in diagnostic biopsy; (c) validate the utility of glycoproteins separately and in combination to predict prostate cancer with a higher tumor grade (i.e., Gleason 3+4 or greater) at radical prostatectomy with NCI-EDRN Tissue Upgrading cohort. 2. Develop and apply ELISA assays to verify the candidate glycoproteins as non-invasive urinary tests for detecting aggressive prostate cancer.

Analytic Method

No analytic method available.

Outcome

see Objectives

Publications

• No publications available at this time for this protocol.

Biomarkers

• ACP3
• DSC2
• PTGDS
• TMPRSS2

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Aug 1 2019

Estimated Finish Date

Mar 31 2021

Finish Date

Feb 5 2021

Protocol ID

460

Protocol Type

Reference Set

Fields of Research

• Glycomics
• Proteomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate

Phased Status

2